Technical Analysis for VBS - Vectus Biosystems Ltd
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
Stochastic Buy Signal | Bullish | 0.00% | |
Narrow Range Bar | Range Contraction | 10.00% | |
Stochastic Reached Oversold | Weakness | 10.00% | |
Wide Bands | Range Expansion | 10.00% | |
Oversold Stochastic | Weakness | 10.00% | |
Narrow Range Bar | Range Contraction | 10.00% | |
Wide Bands | Range Expansion | 10.00% | |
Gapped Down | Weakness | 10.00% | |
Narrow Range Bar | Range Contraction | 10.00% |
Alert | Time |
---|---|
Rose Above Previous Day's High | 6 days ago |
Rose Above 20 DMA | 6 days ago |
Rose Above 10 DMA | 6 days ago |
Up 1 ATR | 6 days ago |
Up 5% | 6 days ago |
Get a Trading Assistant
Vectus Biosystems Ltd Description
Vectus Biosystems Limited is engaged in medical Research and Development. The Company's drug candidates can be orally administered. The Company's primary lead compound, VB0004, has been shown to be both anti-hypertensive and anti-fibrotic in the heart and kidneys. Using its platform technology, the Company has constructed a library of more than 200 small molecules with varying degrees of anti-hypertensive and/or anti-fibrotic properties. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH), as well as pulmonary fibrotic diseases. Accugen is a platform, developed by the Company's subsidiary, Accugen Pty Limited. Accugen comprises reagents and software that quantitate quantitative polymerase chain reaction (qPCR) reactions, which measures the amount of Deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in a sample. It identifies drug targets with specific activity in the heart, kidneys, lungs and liver.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Software Medicine Disease Diseases Pound Heart Platform Technology Medical Research Fibrosis Hepatitis Fibrotic Diseases Polymerase Chain Reaction Steatohepatitis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.38 |
52 Week Low | 0.2 |
Average Volume | 16,323 |
200-Day Moving Average | 0.564 |
50-Day Moving Average | 0.284 |
20-Day Moving Average | 0.262 |
10-Day Moving Average | 0.257 |
Average True Range | 0.018 |
RSI (14) | 51.46 |
ADX | 24.71 |
+DI | 37.292 |
-DI | 42.521 |
Chandelier Exit (Long, 3 ATRs) | 0.242 |
Chandelier Exit (Short, 3 ATRs) | 0.253 |
Upper Bollinger Bands | 0.294 |
Lower Bollinger Band | 0.230 |
Percent B (%b) | 0.71 |
BandWidth | 24.217 |
MACD Line | -0.009 |
MACD Signal Line | -0.011 |
MACD Histogram | 0.0023 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.313 | ||||
Resistance 3 (R3) | 0.308 | 0.292 | 0.306 | ||
Resistance 2 (R2) | 0.292 | 0.282 | 0.294 | 0.304 | |
Resistance 1 (R1) | 0.283 | 0.276 | 0.288 | 0.288 | 0.302 |
Pivot Point | 0.267 | 0.267 | 0.269 | 0.269 | 0.267 |
Support 1 (S1) | 0.258 | 0.257 | 0.263 | 0.263 | 0.248 |
Support 2 (S2) | 0.242 | 0.251 | 0.244 | 0.246 | |
Support 3 (S3) | 0.233 | 0.242 | 0.244 | ||
Support 4 (S4) | 0.238 |